Ambrisentan blocks receptors responsible for vasoconstriction for pulmonary hypertension. By reducing excessive force within the pulmonary vasculature, the therapy supports improved cardiac output and decreases vascular resistance in patients.
Classified among endothelin-type A receptor antagonists, this active compound limits the narrowing of blood vessels that contributes to elevated pressure in the lungs. By binding selectively to the endothelin-A receptor, it helps maintain smoother blood flow in the pulmonary circulation. The substance appears in medicines such as Letairis, which are used under the oversight of Singapore’s Health Sciences Authority.
Formulated as Letairis tablets, the agent is marketed both as a generic option and under its brand name across Singaporean pharmacies. Tablet strengths typically range from 5 mg to 10 mg, allowing clinicians to tailor therapy based on individual assessment. The product is supplied in blister packs that protect each dose from moisture, and it adheres to local labeling standards set by the HSA.
Targeting increased pulmonary arterial pressure, the drug assists adults diagnosed with pulmonary arterial hypertension (PAH). It is commonly employed when patients experience shortness of breath during routine activities, fatigue, or chest discomfort due to reduced oxygen delivery. Specialists may consider it for individuals whose PAH is classified as WHO Group 1, especially when other vasodilators have been insufficient. The medication also finds use in combination regimens aimed at stabilizing long-term heart-lung function.
By blocking endothelin-A receptors on the surface of vascular smooth muscle, it reduces the signal that normally triggers tightening of the arteries in the lungs. This action allows the vessels to remain more relaxed, thereby lowering resistance to blood flow and easing the workload on the right side of the heart. The effect is gradual, often observed over several weeks of consistent intake.
Mild headache, nasal congestion, and occasional nausea may appear during the first weeks of therapy, typically resolving without intervention.
Rare but urgent signs include sudden breathing difficulty, swelling of the face or limbs, and unexplained liver discomfort; any of these warrant immediate medical attention.
Pregnant individuals, patients with severe liver impairment, and those with known hypersensitivity to endothelin-type A antagonists should avoid this treatment.
Alcohol consumption may amplify dizziness, while concurrent use of certain anticoagulants or enzyme-inducing agents can alter drug levels; always refer to the specific medication’s insert for a complete interaction list.
Storing the tablets in a dry, room-temperature environment helps preserve potency throughout the prescribed course. Treatment duration varies; some users require short-term stabilization, whereas others continue therapy for years under ongoing monitoring. For detailed usage, dosing, and administration, refer to the specific medication's clinical information.
This overview of ambrisentan is intended for educational purposes only and does not constitute medical advice; individual medicines such as Letairis differ in strength, formulation, and instructions; the information provided here carries no liability for any clinical application; patients should review the specific medication labeling and consult a licensed healthcare professional for personalized guidance.
